# Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is a public company listed on Nasdaq as GRCE, headquartered in Princeton, NJ, United States.

## Company overview

- **Legal name:** Grace Therapeutics, Inc.
- **Former names in filing history:** Acasti Pharma Inc. (2008-09-02 to 2024-10-25)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Princeton, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** March 31
- **Ticker:** Nasdaq: GRCE
- **SEC CIK:** 0001444192

## About

Grace Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001444192, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-06-18, it reported net income of USD -7,793,000; total assets of USD 66,654,000 for the fiscal period ended 2026-03-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2026 (period ended 2026-03-31)

- **Net income:** -$7.8M (USD -7,793,000)
- **Total assets:** $66.7M (USD 66,654,000)
- **Cash and equivalents:** $17.0M (USD 16,977,000)
- **Operating cash flow:** -$8.9M (USD -8,869,000)

### FY2025 (period ended 2025-03-31)

- **Net income:** -$9.6M (USD -9,568,000)
- **Total assets:** $72.0M (USD 71,993,000)
- **Cash and equivalents:** $22.1M (USD 22,133,000)
- **Operating cash flow:** -$14.9M (USD -14,904,000)

### FY2024 (period ended 2024-03-31)

- **Net income:** -$12.9M (USD -12,853,000)
- **Total assets:** $73.3M (USD 73,300,000)
- **Cash and equivalents:** $23.0M (USD 23,005,000)
- **Operating cash flow:** -$12.3M (USD -12,333,000)

### FY2023 (period ended 2023-03-31)

- **Net income:** -$42.4M (USD -42,429,000)
- **Total assets:** $79.1M (USD 79,123,000)
- **Cash and equivalents:** $27.9M (USD 27,875,000)
- **Operating cash flow:** -$15.9M (USD -15,913,000)

## Recent SEC filings

- Form 8-K — filed 2026-09-18 — period 2026-09-17 — 8-K
- Form 8-K — filed 2026-08-13 — period 2026-08-13 — 8-K
- Form 10-Q — filed 2026-08-13 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-06 — period 2026-08-04 — 8-K
- Form DEF 14A — filed 2026-07-28 — period 2026-09-17 — DEF 14A
- Form 8-K — filed 2026-07-28 — period 2026-07-28 — 8-K
- Form 8-K — filed 2026-06-18 — period 2026-06-18 — 8-K
- Form 8-K — filed 2026-06-18 — period 2026-06-18 — 8-K
- Form 10-K — filed 2026-06-18 — period 2026-03-31 — 10-K
- Form 8-K — filed 2026-06-05 — period 2026-06-01 — 8-K
- Form 8-K — filed 2026-04-27 — period 2026-04-27 — 8-K
- Form 8-K — filed 2026-04-23 — period 2026-04-23 — 8-K

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/grace-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology